insights_auto
Why is DMYD-B up 3,47%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
1,01 SEK
arrow_upward
+3,47%(+0,034) 1D
12 ოქტ, 17:29:58 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
0,98 SEK
High
1,04 SEK
Low
0,98 SEK
Mkt. cap
153,60 მლნ.
Avg. vol.
773,64 ათ.
Volume
796,60 ათ.
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 მლნ.
No. of employees
42
Open
0,98 SEK
High
1,04 SEK
Low
0,98 SEK
Mkt. cap
153,60 მლნ.
Avg. vol.
773,64 ათ.
Volume
796,60 ათ.
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 მლნ.
No. of employees
42
News stories
From web sources and news partners
Foreign Policy Journal
·
18 წუთის წინ
SoundHound AI (NASDAQ: SOUN) Slides 46% In 2026 As Cash Burn Outpaces Revenue Growth
openPR.com
·
27 წუთის წინ
Best Crypto Presale to Buy as 473M XRP Hits Nasdaq: Is Pepeto Beating SOL and HYPE?
MarketBeat
·
9 წუთის წინ
eBay (NASDAQ:EBAY) Stock Price Up 4.3% - Time to Buy?
Seeking Alpha
·
32 წუთის წინ
S&P 500 expected to see 25% EPS growth as earnings kick off (SP500:)
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB